Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 1, 2008, Pages 79-87

  Horiguchi, A ^a   Chen, D Y T ^b   Goodman, O B ^a   Zheng, R ^a   Shen, R ^a   Guan, H ^c   Hersh, L B ^c   Nanus, D M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MEMBRANE METALLOENDOPEPTIDASE; MUTANT PROTEIN; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; SMOOTH MUSCLE ACTIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CATALYSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SUPERNATANT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LENTIVIRUS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NEPRILYSIN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39149103093     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500984     Document Type: Article

References (40)

1. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991; 88: 10662-10666.
2. Turner AJ, Isaac RE, Coates D. The nepriIysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 2001; 23: 261-269.
3. Goodman OG, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein. RL et al. Neutral endopeptidase inhibits angiogenesis via proteolysis of basic fibroblast growth factor (FGF-2). J Biol Chem 2006; 281 33597-33605.
4. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4: 50-57.
5. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG et al Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000; 6: 1664-1670.
6. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004; 10: 4096-4100.
7. Sumitomo M, Milowsky MI, Shen F, Navarro D, Dai J, Asano T et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001; 61: 3294-3298.
8. Dawson LA, Maitland NJ, Turner AJ, Usmani BA. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer 2004; 90 1577-1582.
9. Osman I, Dai J, Mikhail M, Navarro D, Taneja SS, Lee P et al. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 2006; 107 2628-2636.
10. van Bokhoven A, Varella-Garria M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001; 61: 6340-6344.
11. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D et al. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res 2001; 7: 1370-1377.
12. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.
13. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2O03; 23: 1992-1996.
14. Pellinen F, Hakkarainen T, Walifors T, Tulimaki K, Ketola A, Tenhuneh A et al. Cancer cells as targets for Ientivirus-mediated gene transfer and gene therapy. Int J Oncol 2004; 25: 1753-1762.
15. Bastide C, Maroc N, Bladou F, Hassoun J, Maitland N, Mannoni P et al Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo. Prostate Cancer Prostatic Dis 2003; 6: 228-234.
16. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-635.
17. Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate 2004; 59: 370-382.
18. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003; 10: 764-770.
19. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346-352.
20. Jiang G, Li J, Zeng Z, Man L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006; 5: 435-440.
21. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13 1023-1032.
22. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004; 23: 6031-6039.
23. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U et al. Leptin induces endothelial cell migration through Akt, Which is inhibited by PPARgamma-figands. Hypertension 2002; 40: 748--754.
24. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M et al. Androgen-induced growth inhibition of androgen receptor expressing- androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000; 141: 1699-1704.
25. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Hpyakawa M. 3,hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648-8655.
26. Sumitomo M, lwase A, Zheng R, Navarro D, Kaminetzky D, Shen R et al Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004; 5: 67-78.
27. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399-1407.
28. Aoyagi Y, Oda T, Kinoshita T, Nakahashi C, Hasebe T, Ohkohchi N et al Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br J Cancer 2004; 91: 1316-1326.
29. Smith JA, Madden T, Vijjeswarapu M, Newman RA. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem Pharmacol 2001; 62: 469-472.
30. Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D et al Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin Cancer Res 2002; 8: 2647-2654.
31. Turner AJ. Exploring the structure and function of zinc metallopeptidases: Old enzymes and new discoveries. Biochem Soc Trans 2003; 31: 723-727.
32. Scholzen TE, Luger TA. Neutral endopeptidase and angiotensin-converting enzyme - key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 2004; 13 (Suppl 4): 22-26.
33. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997; 33: 225-232.
34. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004; 165: 1543-1556.
35. Wesley W McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005; 65 1325-1334.
36. Polnaszek N, Kwabi-Addo 13, Peterson LE, Ozen M, Greenberg NM, Ortega S. et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63: 5754-5760.
37. Nakamoto T, Chang CS, Li AK, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1092; 52: 571-577.
38. Giavazzi P, Sennino, B, Coltrini D, Garofalo A, Dossi R, Ronca R et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003; 162: 1913-1926.
39. Nicholson,B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004; 91: 125-150.
40. MacRae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, qMaitland N et al. Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate 2006; 66: 470-494.